Browsing Tag
NASDAQ
806 posts
Corcept Therapeutics (CORT) CATALYST data puts Korlym at centre of difficult-to-control diabetes strategy
Find out how Corcept Therapeutics’ ADA data could reshape cortisol screening in hard-to-control diabetes and GLP-1 care.
Honeywell International Inc. prepares for HONA debut as aerospace separation enters final stretch
Honeywell sets the HONA spin-off date and reverse split plan, putting HON stock into a sharper valuation test. Read what changes next.
Why TEM stock sentiment could hinge on Tempus AI’s FDA-approved diagnostics expansion
Find out how Tempus AI’s xT CDx approval could strengthen TEM stock sentiment, oncology diagnostics growth, and ADLT pricing strategy.
Why Joenja’s pediatric expansion could strengthen Pharming Group’s long-term commercial runway
Find out how Pharming’s Joenja FDA review could affect PHAR stock sentiment, pediatric APDS access, and rare-disease revenue growth.
Almonty Industries prices $700m notes as $AII investors assess tungsten expansion funding
Almonty Industries priced US$700m convertible notes as tungsten demand rises. Find out what the $AII financing means next.
Good news, bad market: how 172,000 jobs triggered the worst chip day since 2020
A blowout 172K jobs report sparked Fed rate-hike fears and a chip rout, sending the Nasdaq down 4% and the semiconductor index to its worst day since 2020.
AST SpaceMobile (NASDAQ: ASTS) heads into a make-or-break mid-June satellite launch
AST SpaceMobile (NASDAQ: ASTS) is worth US$44bn with no live network and tiny revenue. Three BlueBird launches this month will test the whole story.
Rigetti Computing (NASDAQ: RGTI) rides a $2bn quantum funding wave into late 2026
Rigetti Computing (NASDAQ: RGTI) makes US$4.4m a quarter and is worth billions. A US$2bn federal quantum push is now deciding whether the bet pays.
POET Technologies (NASDAQ: POET) chases a $500m AI optics deal under a legal cloud
POET Technologies (NASDAQ: POET) made US$503k last quarter but signed a US$500m AI optics deal. A June 29 lawsuit deadline now frames the whole story.
Why GILD stock sentiment may depend on more than one positive Phase 3 liver disease result
Find out why GILD stock sentiment may need more than positive Livdelzi data as investors weigh Gilead’s liver disease growth strategy.